<DOC>
	<DOCNO>NCT02851407</DOCNO>
	<brief_summary>This study compare efficacy safety defibrotide versus best supportive care prevention hepatic veno-occlusive disease ( VOD ) adult pediatric patient undergo hematopoietic stem cell transplant high risk high risk develop VOD .</brief_summary>
	<brief_title>Study Comparing Efficacy Safety Defibrotide v Best Supportive Care Prevention Hepatic Veno-Occlusive Disease Adult Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>1 . Patient must age 1 month start date study treatment . 2 . Patient must schedule undergo allogeneic autologous hematopoietic stem cell transplant ( HSCT ) ( adults pediatric patient ) autologous HSCT ( pediatric patient ) high risk high risk develop venoocclusive disease ( VOD ) . 3 . Female patient childbearing potential sexually active must agree use medically acceptable method contraception throughout entire study period 4 week last dose study drug ; male patient female partner childbearing potential must agree use medically acceptable method contraception 6 month last dose study drug . 4 . Patient and/or legal guardian representative must able understand sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 1 . Patient hemodynamic instability within 24 hour start study treatment . 2 . Patient acute bleed clinically significant within 24 hour start study treatment . 3 . Patient use medication increase risk bleed within 24 hour start study treatment . 4 . Patient use plan use investigational agent prevention treatment VOD . 5 . Patient , opinion investigator , may able comply safety monitoring requirement study . 6 . Patient psychiatric illness would prevent patient legal guardian representative give informed consent and/or assent . 7 . Patient serious active disease comorbid medical condition , judge investigator , would interfere conduct study . 8 . Patient pregnant lactating agree stop breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>hematopoietic stem cell transplant ( HSCT )</keyword>
	<keyword>veno-occlusive disease ( VOD )</keyword>
	<keyword>sinosoidial obstruction syndrome ( SOS )</keyword>
</DOC>